Using Adeno-associated viruses, LEXEO Therapeutics is developing a diverse pipeline of gene therapy candidates to address rare and non-rare monogenic diseases, hereditary and acquired diseases across a spectrum of patient population sizes, and a range of unmet medical needs. The company collaborates with Weill Cornell Medicine’s Department of Genetic Medicine to advance its pre-clinical pipeline and aims to advance clinical programs through to commercialization. LEXEO Therapeutics has partnerships and exclusive licenses with leading academic laboratories and is led by experts in genetic medicines, rare disease drug development, manufacturing, and commercialization.